Prognostic factors for mesothelioma

Hematology/Oncology Clinics of North America

Volumn 19, Issue 6, 2005, Pages 1041-1052

  Steele, Jeremy P C ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

AGE DISTRIBUTION; CANCER SURGERY; CANCER SURVIVAL; CELL TYPE; CLINICAL FEATURE; GENE EXPRESSION PROFILING; HUMAN; LEUKEMIA; LEUKOCYTOSIS; MEDICAL RESEARCH; MESOTHELIOMA; ORGANIZATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCORING SYSTEM; SEX DIFFERENCE; THORAX PAIN; THROMBOCYTOSIS; VALIDATION PROCESS; WEIGHT REDUCTION;

HUMANS; MESOTHELIOMA; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 28444498381     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2005.09.009     Document Type: Review

References (31)

1. B.W. Robinson, A.W. Musk, and R.A. Lake Malignant mesothelioma Lancet 366 9483 2005 397 408
2. N.J. Vogelzang, J.J. Rusthoven, and J. Symanowski Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 14 2003 2636 2644
3. D.A. Fennell, and R.M. Rudd Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development Lancet Oncol 5 6 2004 354 362
4. D.J. Sugarbaker, R.M. Flores, and M.T. Jaklitsch Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients J Thorac Cardiovasc Surg 117 1 1999 54 63
5. V.W. Rusch, K. Rosenzweig, and E. Venkatraman A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma Thorac Cardiovasc Surg 122 4 2001 788 795
6. D.J. Sugarbaker, M.T. Jaklitsch, and R. Bueno Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies J Thorac Cardiovasc Surg 128 1 2004 138 146
7. D.J. Stewart, A.E. Martin-Ucar, and J.G. Edwards Extra-pleural pneumonectomy for malignant pleural mesothelioma: the risks of induction chemotherapy, right-sided procedures and prolonged operations Eur J Cardiothorac Surg 27 3 2005 373 378
8. National Cancer Research Network (UK): Trials database Available at: http://www.ncrn.org.uk/portfolio/ Accessed August 31, 2005
9. J.P. Steele, and R.M. Rudd Malignant mesothelioma: predictors of prognosis and clinical trials Thorax 55 9 2000 725 726
10. V.W. Rusch A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group Lung Cancer 14 1 1996 1 12
11. J.P. van Meerbeeck, and M. Boyer Consensus report: pretreatment minimal staging and treatment of potentially resectable malignant pleural mesothelioma Lung Cancer 49 Suppl 1 2005 S123 S127
12. D. Curran, T. Sahmoud, and P. Therasse Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience J Clin Oncol 16 1 1998 145 152
13. J.E. Herndon, M.R. Green, and A.P. Chahinian Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B Chest 113 3 1998 723 731
14. J.G. Edwards, K.R. Abrams, and J.N. Leverment Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems Thorax 55 9 2000 731 735
15. D.A. Fennell, A. Parmar, and J. Shamash Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials J Clin Oncol 23 1 2005 184 189
16. J.P. Steele, J. Shamash, and M.T. Evans Phase II study of vinorelbine in patients with malignant pleural mesothelioma J Clin Oncol 18 23 2000 3912 3917
17. D.A. Fennell, J.P. Steele, and J. Shamash Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma Lung Cancer 47 2 2005 277 281
18. D. Fennell, J. Steele, and J. Shamash A phase II study of irinotecan, cisplatin, and mitomycin C (IPM) in malignant pleural mesothelioma [abstract P517] Lung Cancer 41 Suppl 2 2003 S221
19. M.F. Muers, R.M. Rudd, and M.E. O'Brien BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma Thorax 59 2 2004 144 148
20. G.W. Middleton, I.E. Smith, and M.E. O'Brien Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma Ann Oncol 9 3 1998 269 273
21. P. Kumar, and R.A. Kratzke Molecular prognostic markers in malignant mesothelioma Lung Cancer 49 Suppl 1 2005 S53 S60
22. D.A. Fennell, A. Klabatsa, and M.T. Sheaff Identification of glucose transporter type 1 overexpression as a predictor of survival in patients with malignant pleural mesothelioma [abstract 7199] J Clin Oncol 22 2004 14S
23. J.G. Edwards, S.P. Faux, and S.M. Plummer Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma Clin Cancer Res 8 6 2002 1857 1862
24. B.W. Robinson, J. Creaney, and R. Lake Mesothelin-family proteins and diagnosis of mesothelioma Lancet 362 9396 2003 1612 1616
25. H.I. Pass, Z. Liu, and A. Wali Gene expression profiles predict survival and progression of pleural mesothelioma Clin Cancer Res 10 3 2004 849 859
26. G.J. Gordon, G.N. Rockwell, and P.A. Godfrey Validation of genomics-based prognostic tests in malignant pleural mesothelioma Clin Cancer Res 11 12 2005 4406 4414
27. F. Lopez-Rios, S. Chuai, and S. Hussain Gene expression profiling of malignant mesothelioma for prognostic prediction and identification of potential therapeutic targets and differential diagnostic markers [abstract O78] Lung Cancer 49 Suppl 2 2005 S29
28. R. Flores, M. Zakowski, and E. Venkatramen Malignant pleural mesothelioma (MPM): new predictors of survival and analysis of the impact of current treatment [abstract O75] Lung Cancer 49 Suppl 2 2005 S28
29. R.M. Flores The role of PET in the surgical management of malignant pleural mesothelioma Lung Cancer 49 Suppl 1 2005 S27 S32
30. I. Roushdy-Hammady, J. Siegel, and S. Emri Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey Lancet 357 9254 2001 444 445
31. S. Emri, and A.U. Demir Malignant pleural mesothelioma in Turkey, 2000-2002 Lung Cancer 45 Suppl 1 2004 S17 S20